Merck - LYNPARZA (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer.

ENPNewswire-August 5, 2022--Merck - LYNPARZA (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

(C)2022 ENPublishing - http://www.enpublishing.co.uk

Release date- 04082022 - RAHWAY, N.J. - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

This approval by the EC was based on results from the Phase 3 OlympiA trial...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT